A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-13

Study Completion Date

2022-01-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin \[cis\] plus gemcitabine \[gem\])

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

NCT05065957

Biliary Tract Cancer

RECRUITING PHASE2/PHASE3

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

NCT00553332

Liver and Intrahepatic Biliary Tract Cancer Recurrent Extrahepatic Bile Duct Cancer Unresectable Extrahepatic Bile Duct Cancer

COMPLETED PHASE2

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

NCT04238637

Intrahepatic Cholangiocarcinoma

ACTIVE_NOT_RECRUITING PHASE2

Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma

NCT06903273

Cholangiocarcinoma Biliary Tract Cancer (BTC)

NOT_YET_RECRUITING PHASE2

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553

Biliary Tract Cancer Metastatic Cancer Advanced Cancer

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy cis plus gem in patients with unresectable, locally advanced, recurrent or metastatic biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer), who are naïve to tumor-directed therapy in the locally advanced or metastatic setting, and for which treatment with 1L therapy (defined as a combination of cis plus gem) is planned.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Biliary Tract Cancer (BTC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xermelo 250mg plus first line therapy for a week, then Xermelo 500mg

Xermelo 250 milligram (mg) plus first line therapy for a week, then Xermelo 500mg plus first line therapy for the duration of the study

Group Type EXPERIMENTAL

telotristat ethyl

Intervention Type DRUG

XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

telotristat ethyl

XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

telotristat ethyl + (cisplatin [cis] plus gemcitabine [gem])

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female adults, ≥18 years of age. Patients of childbearing potential must agree to use an adequate method of contraception during the study and for 30 days after the last dose of XERMELO
* Histopathologically or cytologically-confirmed, unresectable, locally advanced, recurrent, or metastatic biliary tract cancer (BTC)
* Naïve to tumor-directed therapy in locally advanced, unresectable, or metastatic setting
* Measurable disease
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Plans to initiate treatment with 1L therapy (cisplatin plus gemcitabine)
* Ability to provide written informed consent prior to participation in any study-related procedure

Exclusion Criteria

* Prior exposure to XERMELO, telotristat ethyl, telotristat etiprate, LX1032, or LX1606
* Primary tumor site in the ampulla of Vater
* Treatment with photodynamic therapy for localized disease or to relieve biliary obstruction in the presence of metastatic disease within the past 30 days
* Hematology laboratory values of: a. Absolute neutrophil count (ANC) ≤1,500 cells/mm\^3; or b. Platelets ≤100,000 cells/mm\^3; or c. Hemoglobin (Hgb) ≤9 g/dL; or d. White blood count (WBC) ≤3,000 cells/mm\^3
* Hepatic laboratory values of aspartate aminotransferase (AST) or alanine aminotransferase (ALT): a. \>5 x upper limit of normal (ULN) if patient has documented history of hepatic metastases; or b. \>2.5 x ULN if no liver metastases are present
* Serum albumin \<2.8 g/dL
* Total bilirubin \>1.5 x ULN or \>1.5 mg/dL
* Prothrombin time (PT) or international normalized ratio (INR) \>1.5 x ULN
* Serum creatinine or serum urea \>1.5 x ULN
* Estimated glomerular filtration rate (eGFR) \<50 mL/min
* Positive pregnancy test, pregnant, or breastfeeding
* Any other clinically significant laboratory abnormality that would compromise patient safety or the outcome of the study
* Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study
* Myocardial infarction within the past 6 months
* Active bleeding diathesis
* Life expectancy ≤3 months
* Current complaints of persistent constipation or history of chronic constipation, bowel obstruction or fecaloma within the past 6 months
* Receiving chronic treatment with corticosteroids ≥5 mg of prednisone per day (or equivalent) or other immunosuppressive agent(s)
* History and/or uncontrolled hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV)-1 or HIV-2
* History of substance or alcohol abuse within the past 2 years
* History of galactose intolerance, deficiency of Lapp lactase, or glucose-galactose malabsorption
* History of malignancy or active treatment for malignancy within 5 years
* Receipt of live, attenuated vaccine or close contact with someone who has received a live, attenuated vaccine within the past 1 month
* Receipt of any investigational agent or study treatment (ie, any treatment or therapy not approved by the FDA for the treatment of BTC) within the past 30 days
* Receipt of any protein or antibody-based therapeutic agents within the past 3 months
* Treatment with any tumor-directed therapy within the past 6 months with curative intent
* Existence of any surgical or medical condition that, in the judgment of the Investigator, might compromise patient safety or the outcome of the study
* Presence of any clinically significant findings (relative to the patient population) during review of medical history or upon physical exam that, in the Investigator's or Medical Monitor's opinion, would compromise patient safety or the outcome of the study
* Evidence of brain metastases
* Unable or unwilling to communicate or cooperate with the Investigator for any reason
* Employee of Sponsor or clinical site, or relative of any member of a clinical site's staff

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No